Related Experiment Video
Updated: Dec 1, 2025

Microsatellite DNA Genotyping and Flow Cytometry Ploidy Analyses of Formalin-fixed Paraffin-embedded Hydatidiform Molar Tissues
Published on: October 20, 2019
A diagnostic profile on the PartoSure test.
Safoura Rouholamin1, Maryam Razavi2, Mahroo Rezaeinejad3
1Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences , Isfahan, Iran.
Placental alpha macroglobulin-1 (PAMG-1) via the PartoSure test shows promise for predicting preterm birth (PTB). While effective, it should complement clinical assessments for accurate PTB risk evaluation.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Biomarker Discovery
Background:
- Preterm birth (PTB) is a significant global health concern, affecting over 10% of live births and showing an increasing trend worldwide.
- Existing biomarkers for PTB, such as fetal fibronectin (fFN) and phosphorylated insulin-like growth factor-binding protein-1 (phIGFBP-1), have demonstrated limitations in clinical utility.
- There is a critical need for improved diagnostic tools to enhance the monitoring and management of PTB.
Purpose of the Study:
- To evaluate the clinical utility and limitations of placental alpha macroglobulin-1 (PAMG-1), specifically the PartoSure test, as a biomarker for predicting preterm birth (PTB).
- To compare the performance of PAMG-1 (PartoSure) against traditional PTB biomarkers like fFN and phIGFBP-1.
Main Methods:
- Expert opinion review of current literature on PAMG-1 (PartoSure) for PTB prediction.
- Comparative analysis of diagnostic performance metrics including negative predictive value (NPV), negative likelihood ratio (LR-), specificity, positive predictive value (PPV), and positive likelihood ratio (LR+).
Main Results:
- The PAMG-1 (PartoSure) test demonstrated comparable negative predictive value (NPV) and negative likelihood ratio (LR-) to fFN and phIGFBP-1.
- PAMG-1 (PartoSure) exhibited superior specificity, positive predictive value (PPV), and positive likelihood ratio (LR+) among at-risk pregnant women.
- Despite promising results, the PartoSure test is not an absolute predictor of PTB.
Conclusions:
- PAMG-1 (PartoSure) represents a valuable addition to the diagnostic arsenal for PTB, offering improved specificity and PPV.
- The PartoSure test should be integrated with comprehensive clinical evaluations, including cervical examinations and uterine activity assessments, for optimal PTB risk stratification.
- Further research and clinical validation are essential to fully establish the role of PAMG-1 in managing PTB.
More Related Videos
11:09Multiplex Detection of Bacteria in Complex Clinical and Environmental Samples using Oligonucleotide-coupled Fluorescent Microspheres
Published on: October 23, 2011
10:21A Coregistered Ultrasound and Photoacoustic Imaging Protocol for the Transvaginal Imaging of Ovarian Lesions
Published on: March 3, 2023
Related Concept Videos
Urine Studies II: Urine Culture and Sensitivity Test
Serum Laboratory Studies, Stool Test, Breath Test
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Assessment of the Abdomen III: Palpation
Methods of Documentation II: POMR
Urine Studies I: Urinalysis